Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Syndrome/Interstitial Cystitis.

Trial Profile

Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Syndrome/Interstitial Cystitis.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 May 2011

At a glance

  • Drugs Rezatomidine (Primary)
  • Indications Pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 May 2011 Planned end date (Mar 2007) added as reported by ClinicalTrials.gov.
    • 26 Jun 2007 Status changed from recruiting to discontinued.
    • 13 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top